Leadiant faces Dutch supply-restriction questions over orphan drug's ingredients
Drugmaker Leadiant Biosciences faces questions over whether it is restricting the supply of raw materials for a rare-disease drug as part of a broader Dutch probe into excessive pricing for that...To view the full article, register now.
Already a subscriber? Click here to view full article